Source-grounded facts extracted from HCA Healthcare, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Michael Cuffe departed as Executive Vice President and Chief Clinical Officer at HCA Healthcare, Inc..
“On June 15, 2026, Dr. Michael Cuffe and HCA Healthcare, Inc. (the “Company”) agreed that Dr. Cuffe will step down as Executive Vice President and Chief Clinical Officer effective August 31, 2026, and thereafter continue in a transitional role with the Company until February 2027.”
HCA Healthcare, Inc. entered into Indentures with CSC Delaware Trust Company and Deutsche Bank Trust Company Americas valued at $3,000,000,000 (effective 2026-04-30).
“On April 30, 2026, the Notes were issued pursuant to an indenture dated as of August 1, 2011 (the “Base Indenture”), among the Issuer, the Parent Guarantor, CSC Delaware Trust Company (formerly known as Delaware Trust Company) (as successor to Law Debenture Trust Company of New York), as trustee (the “Trustee”), and Deutsche Bank Trust Company Americas, as paying agent, registrar and transfer agent (the “Paying Agent”), as amended and supplemented by, (i) with respect to the 2031 Notes, the Supplemental Indenture No. 54, dated as of April 30, 2026, among the Issuer, the Parent Guarantor, the Trustee and the Paying Agent (together with the Base Indenture, the “2031 Notes Indenture”); (ii) with respect to the 2033 Notes, the Supplemental Indenture No. 55, dated as of April 30, 2026, among the Issuer, the Parent Guarantor, the Trustee and the Paying Agent (together with the Base Indenture, the “2033 Notes Indenture”); and (iii) with respect to the 2036 Notes, the Supplemental Indenture No”
HCA Healthcare, Inc. reported first quarter ended March 31, 2026 results: revenue $19.109 billion, net income $1.620 billion, EPS $7.15 per diluted share.
“the first quarter ended March 31, 2026. Key first quarter metrics (all percentage changes compare 1Q 2026 to 1Q 2025 unless otherwise noted): • Revenues increased 4.3 percent to $19.109 billion • Net income attributable to HCA Healthcare, Inc. increased 0.6 percent to $1.620 billion • Diluted earnings per share and diluted earnings per share, as adjusted, increased 10.9”
HCA Healthcare, Inc. incurred senior notes of $3,250,000,000 aggregate principal amount with Public offering at 4.300%, 4.600%, 4.900%, 5.700% maturing 2030 Notes mature November 15, 2030; 2032 Notes mature November 15, 2032; 2035 Notes mature November 15, 2035; 2055 Notes mature November 15, 2055.
“any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement. Issuance of $3,250,000,000 aggregate principal amount of senior notes Overview On October 31, 2025, HCA Inc. (the “Issuer”), a direct, wholly owned subsidiary of HCA Healthcare, Inc. (the “Parent”
HCA Healthcare, Inc.: Amended certificate of incorporation to provide for exculpation of officers as permitted by Delaware law (effective 2025-04-25).
“On April 24, 2025, the Company filed the Certificate of Amendment with the Delaware Secretary of State, to be effective April 25, 2025. A copy of the Certificate of Amendment, as filed with the Delaware Secretary of State, is attached hereto as Exhibit 3.1 and is incorporated herein by reference.”
Meg G. Crofton retired as Director at HCA Healthcare, Inc..
“Retirement of Meg G. Crofton from the”
Christopher F. Wyatt was appointed as Senior Vice President and Controller at HCA Healthcare, Inc..
“In conjunction with Mr. Rutherford’s retirement, Christopher F. Wyatt, age 47, will succeed Mr. Rutherford as principal accounting officer, effective May 1, 2024.”
William B. Rutherford departed as Executive Vice President, Chief Financial Officer, principal financial officer and principal accounting officer at HCA Healthcare, Inc..
“As previously announced, William B. Rutherford, HCA Healthcare, Inc.’s (the “Company’s”) Executive Vice President, Chief Financial Officer, principal financial officer and principal accounting officer notified the Company of his intent to retire, effective May 1, 2024.”
HCA Healthcare, Inc. reported the first quarter ended March 31, 2024 results: revenue $17.339 billion, net income $1.591 billion, EPS $5.93 per diluted share. Guidance reaffirmed.
“HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the first quarter ended March 31, 2024. Key first quarter metrics (all percentage changes compare 1Q 2024 to 1Q 2023 unless otherwise noted): ● Revenues totaled $17.339 billion ● Net income attributable to HCA Healthcare, Inc. totaled $1.591 billion, or $5.93 per diluted share”
Michael R. McAlevey was appointed as Executive Vice President – Chief Legal and Administrative Officer at HCA Healthcare, Inc..
“• 85% of base salary for Michael R. McAlevey, our Senior Vice President and Chief Legal Officer (to be increased to 100%, effective April 1, 2024, in connection with Mr. McAlevey’s appointment as Executive Vice President – Chief Legal and Administrative Officer).”
William B. Rutherford departed as Executive Vice President and Chief Financial Officer at HCA Healthcare, Inc..
“William B. Rutherford intends to retire as Executive Vice President and Chief Financial Officer, effective May 1, 2024, and will therefore not participate in the Executive Officer PEP.”
HCA Healthcare, Inc. incurred senior notes of $4,500,000,000 aggregate principal amount of senior notes with public offering at 5.450%, 5.600%, 6.000%, and 6.100% maturing 2031, 2034, 2054, 2064.
“any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement. Issuance of $4,500,000,000 aggregate principal amount of senior notes Overview On February 23, 2024, HCA Inc. (the “Issuer”), a direct, wholly owned subsidiary of HCA Healthcare, Inc. (the “Parent”
HCA Healthcare, Inc. reported 2024 results: revenue $67.75 to $70.25 billion, net income $5.20 to $5.60 billion, EPS $19.70 to $21.20 per diluted share. Guidance initiated.
“Today, the Company issued the following estimated guidance for 2024: 2024 Guidance Range Revenues $67.75 to $70.25 billion Net Income Attributable to HCA Healthcare, Inc. $5.20 to $5.60 billion Adjusted EBITDA $12.85 to $13.55 billion EPS (diluted) $19.70 to $21.20 per diluted share”
HCA Healthcare, Inc. reported the year ended December 31, 2023 results: revenue $64.968 billion, net income $5.242 billion, EPS $18.97 per diluted share. Guidance initiated.
“Revenues for the year ended December 31, 2023 totaled $64.968 billion, compared to $60.233 billion for the year ended December 31, 2022. Net income attributable to HCA Healthcare, Inc. was $5.242 billion, or $18.97 per diluted share, for the year ended December 31, 2023 compared to $5.643 billion, or $19.15 per diluted share, for the year ended December 31, 2022.”
HCA Healthcare, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $17.303 billion, net income $1.607 billion, EPS $5.93 per diluted share. Guidance initiated.
“Revenues in the fourth quarter of 2023 totaled $17.303 billion, compared to $15.497 billion in the fourth quarter of 2022. Net income attributable to HCA Healthcare, Inc. totaled $1.607 billion, or $5.93 per diluted share, compared to $2.081 billion, or $7.28 per diluted share, in the fourth quarter of 2022.”
Michael A. Marks was appointed as Executive Vice President and Chief Financial Officer at HCA Healthcare, Inc..
“On January 30, 2024, the Company announced that Michael A. Marks, age 54, will succeed Mr. Rutherford as Executive Vice President and Chief Financial Officer, effective May 1, 2024.”
William B. Rutherford retired as Executive Vice President and Chief Financial Officer at HCA Healthcare, Inc..
“On January 24, 2024, William B. Rutherford notified the Company of his intent to retire from his position as Executive Vice President and Chief Financial Officer, effective May 1, 2024.”
HCA Healthcare, Inc. updated its year ending December 31, 2023 guidance (reaffirmed).
“The 2023 guidance ranges for the year have been revised from our second quarter release as follows: Previous 2023 Guidance Range as of July 27, 2023 2023 Guidance Range as of October 24, 2023 Revenues $63.25 to $64.75 billion $63.5 to $64.5 billion Net Income Attributable to HCA Healthcare, Inc. $4.900 to $5.255 billion $4.940 to $5.130 billion Adjusted EBITDA $12.3 to $12.8 billion $12.3 to $12.6 billion EPS (diluted) $17.70 to $18.90 per diluted share $17.80 to $18.50 per diluted share”
HCA Healthcare, Inc. reported third quarter ended September 30, 2023 results: revenue $16.213 billion, net income $1.079 billion, EPS $3.91 per diluted share.
“results for the third quarter ended September 30, 2023. Key third quarter metrics (all percentage changes compare 3Q 2023 to 3Q 2022 unless otherwise noted): ● Revenues totaled $16.213 billion ● Net income attributable to HCA Healthcare, Inc. totaled $1.079 billion, or $3.91 per diluted share ● Adjusted EBITDA totaled $2.880 billion ● Cash flows from operating”
HCA Healthcare, Inc. entered into Indentures valued at $3,250,000,000 aggregate principal amount (effective 2023-05-04).
“On May 4, 2023, the Notes were issued pursuant to an indenture dated as of August 1, 2011 (the “Base Indenture"), among the Issuer, the Parent Guarantor, Delaware Trust Company (as successor to Law Debenture Trust Company of New York), as trustee (the “Trustee"), and Deutsche Bank Trust Company Americas, as paying agent, registrar and transfer agent (the “Paying Agent"), as amended and supplemented by, (i) the Supplemental Indenture No. 34, dated as of May 4, 2023, among the Issuer, the Parent Guarantor, the Trustee and the Paying Agent, relating to the 2028 Notes (together with the Base Indenture, the “2028 Notes Indenture"); (ii) the Supplemental Indenture No. 35, dated as of May 4, 2023, among the Issuer, the Parent Guarantor, the Trustee and the Paying Agent, relating to the 2033 Notes (together with the Base Indenture, the “2033 Notes Indenture") and (iii) the Supplemental Indenture No. 36, dated as of May 4, 2023, among the Issuer, the Parent Guarantor, the Trustee and the Paying”
HCA Healthcare, Inc. reported Full year 2023 results: revenue $62.5 to $64.5 billion, net income $4.750 to $5.160 billion, EPS $17.25 to $18.55 per diluted share. Guidance raised.
“The 2023 guidance ranges for the year have been revised from our fourth quarter release as follows: Previous 2023 Guidance Range as of January 27, 2023 2023 Guidance Range as of April 21, 2023 Revenues $61.5 to 63.5 billion $62.5 to $64.5 billion Net Income Attributable to HCA Healthcare, Inc. $4.525 to $4.895 billion $4.750 to $5.160 billion Adjusted EBITDA $11.8 to $12.4 billion $12.1 to $12.7 billion EPS (diluted) $16.40 to $17.60 per diluted share $17.25 to $18.55 per diluted share”
HCA Healthcare, Inc. reported first quarter ended March 31, 2023 results: revenue $15.591 billion, net income $1.363 billion, EPS $4.85 per diluted share.
“Revenues in the first quarter of 2023 increased to $15.591 billion, compared to $14.945 billion in the first quarter of 2022. Net income attributable to HCA Healthcare, Inc. totaled $1.363 billion, or $4.85 per diluted share, compared to $1.273 billion, or $4.14 per diluted share, in the first quarter of 2022.”
HCA Healthcare, Inc. shareholders rejected Stockholder proposal regarding an amendment to the Patient Safety and Quality of Care Committee charter at the 2023-04-19 meeting.
“6. The stockholder proposal regarding an amendment to the Patient Safety and Quality of Care Committee charter as described in the Company’s 2023 proxy statement was not approved as follows: For Against Abstentions Broker Non-Votes 45,502,303 194,874,882 1,428,412 16,491,171”
HCA Healthcare, Inc. shareholders rejected Stockholder proposal regarding political spending disclosure at the 2023-04-19 meeting.
“5. The stockholder proposal regarding political spending disclosure as described in the Company’s 2023 proxy statement was not approved as follows: For Against Abstentions Broker Non-Votes 56,754,193 184,337,030 714,374 16,491,171”
HCA Healthcare, Inc. shareholders approved Adoption of a non-binding advisory resolution on the Company's named executive officer compensation as described in the Company's 2023 proxy statement at the 2023-04-19 meeting.
“4. The adoption of a non-binding advisory resolution on the Company’s named executive officer compensation as described in the Company’s 2023 proxy statement was approved as follows: For Against Abstentions Broker Non-Votes 230,579,766 10,927,402 298,429 16,491,171”
HCA Healthcare, Inc. shareholders approved Approval of the HCA Healthcare, Inc. 2023 Employee Stock Purchase Plan at the 2023-04-19 meeting.
“3. The HCA Healthcare, Inc. 2023 Employee Stock Purchase Plan was approved as follows: For Against Abstentions Broker Non-Votes 238,190,613 3,161,931 453,053 16,491,171”
HCA Healthcare, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023 at the 2023-04-19 meeting.
“2. The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 was ratified as follows: For Against Abstentions Broker Non-Votes 240,655,160 17,590,706 50,902 0”
HCA Healthcare, Inc. shareholders approved Election of ten director nominees to the Board of Directors for a one-year term at the 2023-04-19 meeting.
“1. The following ten director nominees were elected to the Company’s Board of Directors for a one-year term, or until such director’s respective successor is duly elected and qualified or until such director’s earlier death, resignation or removal, as follows: For Against Abstentions Broker Non-Votes Thomas F. Frist III 236,384,150 5,368,755 52,692 16,491,171 Samuel N. Hazen 240,497,358 1,251,973 56,266 16,491,171 Meg G. Crofton 240,339,619 1,407,995 57,983 16,491,171 Robert J. Dennis 234,067,901 7,671,226 66,470 16,491,171 Nancy-Ann DeParle 238,498,682 3,249,759 57,156 16,491,171 William R. Frist 239,578,134 2,170,833 56,630 16,491,171 Hugh F. Johnston 237,527,316 4,211,331 66,950 16,491,171 Michael W. Michelson 239,631,253 2,109,882 64,462 16,491,171 Wayne J. Riley, M.D. 236,418,547 5,324,531 62,519 16,491,171 Andrea B. Smith 240,803,243 945,476 56,878 16,491,171”
HCA Healthcare, Inc. reported year ended December 31, 2022 results: revenue $60.233 billion, net income $5.643 billion, EPS $19.15 per diluted share. Guidance initiated.
“Revenues for the year ended December 31, 2022 totaled $60.233 billion, compared to $58.752 billion in the same period of 2021.”
HCA Healthcare, Inc. reported fourth quarter ended December 31, 2022 results: revenue $15.497 billion, net income $2.081 billion, EPS $7.28 per diluted share. Guidance initiated.
“results for the fourth quarter ended December 31, 2022. Key fourth quarter metrics (all percentage changes compare 4Q 2022 to 4Q 2021 unless otherwise noted): ● Revenues totaled $15.497 billion ● Net income attributable to HCA Healthcare, Inc. totaled $2.081 billion, or $7.28 per diluted share ● Adjusted EBITDA totaled $3.179 billion ● Cash flows from operating”
HCA Healthcare, Inc. amended ABL Credit Facility valued at $4.5 billion (effective 2023-01-04).
“amended and restated its $4.5 billion senior secured asset-based revolving credit facility (the "ABL Credit Facility") to, among other things, replace LIBOR with Term SOFR as the reference rate available for outstanding and future loans made under the ABL Credit Facility”
HCA Healthcare, Inc. amended Cash Flow Credit Facility valued at $3.5 billion (effective 2023-01-04).
“amended and restated its senior secured credit facility (the "Cash Flow Credit Facility") to, among other things, replace the existing revolving credit commitments of $2.0 billion with a new tranche of revolving credit commitments of $3.5 billion maturing on June 30, 2026”
HCA Healthcare, Inc.: Amended and restated bylaws to revise director nomination and proxy solicitation requirements, including compliance with Rule 14a-19, and incorporate technical conforming changes (effective 2022-12-19).
“On December 19, 2022, the Board of Directors (the “Board”) of HCA Healthcare, Inc. (the “Company”), based on the recommendation of the Nominating and Corporate Governance Committee of the Board, adopted an amendment and restatement of the Company’s Second Amended and Restated Bylaws (as so amended, the “Third Amended Bylaws”), which became effective immediately upon adoption by the Board.”
Jon M. Foster was appointed as Executive Vice President and Chief Operating Officer at HCA Healthcare, Inc..
“On October 20, 2022, the Board of Directors of HCA Healthcare, Inc. (the “Company”) appointed Jon M. Foster as the Executive Vice President and Chief Operating Officer of the Company effective January 1, 2023.”
Charles J. Hall departed as President — National Group at HCA Healthcare, Inc..
“On August 15, 2022, Charles J. Hall, the President — National Group of HCA Healthcare, Inc. (the “Company”), informed the Company that he will retire from the Company, effective December 31, 2022.”
Andrea B. Smith was appointed as director at HCA Healthcare, Inc..
“On January 24, 2022, the Company’s Board of Directors (the “Board”), based on the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Andrea B. Smith to the Company’s Board effective January 26, 2022, increasing the number of directors on the Board from 10 to 11.”
Michael S. Cuffe was appointed as Executive Vice President and Chief Clinical Officer at HCA Healthcare, Inc..
“effective January 1, 2022, Dr. Michael S. Cuffe will become Executive Vice President and Chief Clinical Officer.”
Jonathan B. Perlin departed as President - Clinical Operations Group and Chief Medical Officer at HCA Healthcare, Inc..
“Dr. Jonathan B. Perlin, President - Clinical Operations Group and Chief Medical Officer, notified HCA Healthcare, Inc. (the “Company”) on September 16, 2021 that he had accepted the role of president and CEO of The Joint Commission and will assume his new role on March 1, 2022.”
Hugh F. Johnston was appointed as director at HCA Healthcare, Inc..
“appointed Hugh F. Johnston to the Company’s Board effective September 1, 2021”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.